Share Prices & Company Research

Market News

06 Apr 2021 | 08:08

Oxford Biomedica strikes three-year deal with Boehringer Ingelheim

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new three-year development and supply agreement with Boehringer Ingelheim, it announced on Tuesday, for the manufacture and supply of various types of viral vectors. The FTSE 250 firm said that under the agreement, it would manufacture GMP batches for Boehringer Ingelheim to support the development of viral vectors.

It said the agreement also allowed for the group to manufacture and supply viral vector products in the future.

"This development and supply agreement with Boehringer Ingelheim demonstrates the good progress made in our partnership with Boehringer Ingelheim, which started in 2018," said chief executive officer John Dawson.

"We are proud to be supporting another global pharmaceutical company in the development and manufacturing of their viral vector programs."

Dawson said the company now had a portfolio of partnerships across the development of CAR-Ts, TCR-Ts and in vivo gene therapeutics, using lentiviral vectors.

"We are proud to partner with Boehringer Ingelheim, a business with proven excellence in complex manufacturing projects, as well as expertise in developing innovative medicines for patients with serious unmet medical needs."

At 0819 BST, shares in Oxford Biomedica were up 1.89% at 970p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.